RecruitingMajor Depressive Disorder
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
Eligible age
18–74 yrs
Accepts
All genders
Locations
17 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend
Sponsor: Definium Therapeutics US, Inc.
You may qualify if…
- ✓ 1. Diagnosis of MDD per DSM-5
- ✓ 2. Male or female aged 18 to 74
- ✓ 3. Currently experiencing a major depressive episode (MDE) of ≥8 weeks and ≤24 months duration
- ✓ 4. MADRS Total Score ≥26
- ✓ 5. CGI-S Score ≥4
You may not qualify if…
- ✕ 1. Certain psychiatric disorders (other than major depressive disorder)
- ✕ 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
- ✕ 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine
- ✕ 4. Any clinically significant unstable illness
Where it's recruiting
Source: ClinicalTrials.gov · NCT07592689 · last updated 2026-06-22